News >

ODAC Unanimously Recommends Approval of Tisagenlecleucel for Pediatric ALL

Jason Harris
Published: Wednesday, Jul 12, 2017

Catherine M. Bollard, MD

Catherine M. Bollard, MD
Citing “unprecedented clinical success” and calling the drug “potentially paradigm-changing,” the Oncologic Drugs Advisory Committee (ODAC) voted 10-0 today to recommend approval of a biologics license application (BLA) for tisagenlecleucel (CTL019) for the treatment of patients aged 25 or younger with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL).

The committee was asked to consider 4 issues:
  • Manufacturing quality control with respect to identity, safety, purity and potency
  • Strategies to address safety concerns including generation of replication-competent retrovirus (RCR) and insertional mutagenesis
  • Risk mitigation measures for the serious risks of cytokine release syndrome and neurotoxicity
  • The necessary duration patient follow-up and the type of assessments recommended
The FDA already requires 15 years of follow-up to monitor for subsequent malignant transformation for the tisagenlecleucel investigational new drug studies.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Advances in™ Multiple Myeloma: Changing Treatment Paradigms and the Emerging Potential of CAR T-Cell TherapyAug 30, 20191.5
Publication Bottom Border
Border Publication
x